XLO Xilio Therapeutics, Inc.
Healthcare · Market cap: $46.7M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $0 | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $0 | $0 |
| 2023-Q1 | $0 | $0 |
| 2023-Q2 | $0 | $0 |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $0 | $0 |
| 2024-Q1 | $0 | $4.2K |
| 2024-Q2 | $368.8K | $0 |
| 2024-Q3 | $0 | $0 |
| 2024-Q4 | $1.8M | $0 |
| 2025-Q1 | $0 | $8.6K |
| 2025-Q2 | $73.0K | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $0 | $0 |
| 2026-Q1 | $43.9K | $5.7K |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $0 | $0 |
Bought$2.7M9 buy days
Sold$18.5K7 sell days
Net insider flow+$2.7Mnet buying · 5 years
Latest trade2026-03-26Shannon James Samuel
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Buy | Shannon James Samuel | Director | 5,000 | $8.79 | $43.9K | 1 |
| 2026-01-02 | Sell | Frankenfield Christopher James | CFO | 7,030 | $0.64 | $4.5K | 1 |
| 2026-01-02 | Sell | Brennan Kevin M. | EVP / SVP | 1,826 | $0.64 | $1.2K | 1 |
| 2025-06-17 | Buy | Shannon James Samuel | Director | 25,000 | $0.69 | $17.2K | 1 |
| 2025-06-16 | Buy | Shannon James Samuel | Director | 45,000 | $0.69 | $31.0K | 1 |
| 2025-06-16 | Buy | Russo Rene | CEO | 36,289 | $0.68 | $24.7K | 1 |
| 2025-01-02 | Sell | Frankenfield Christopher James | CFO | 6,954 | $0.98 | $6.8K | 1 |
| 2025-01-02 | Sell | Brennan Kevin M. | EVP / SVP | 1,803 | $0.98 | $1.8K | 1 |
| 2024-12-18 | Buy | GILEAD SCIENCES, INC. | 10% owner | 1,759,978 | $1.04 | $1.8M | 1 |
| 2024-04-02 | Buy | GILEAD SCIENCES, INC. | 10% owner | 485,250 | $0.76 | $368.8K | 1 |
| 2024-02-08 | Sell | Atlas Venture Fund XI, L.P. | 10% owner | 1,000 | $0.64 | $640 | 2 |
| 2024-01-12 | Sell | Atlas Venture Fund XI, L.P. | 10% owner | 2,100 | $0.83 | $1.7K | 2 |
| 2024-01-11 | Sell | Atlas Venture Fund XI, L.P. | 10% owner | 2,135 | $0.87 | $1.9K | 2 |
| 2021-12-10 | Buy | BCIP Life Sciences Associates, LP | 10% owner | 25,000 | $9.65 | $241.2K | 2 |
| 2021-12-09 | Buy | BCIP Life Sciences Associates, LP | 10% owner | 4,011 | $9.84 | $39.5K | 1 |
| 2021-12-08 | Buy | BCIP Life Sciences Associates, LP | 10% owner | 13,458 | $9.62 | $129.5K | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10% owner | $2.2M | $0 | 2024-12-18 |
| BCIP Life Sciences Associates, LP | 10% owner | $410.1K | $0 | 2021-12-10 |
| Shannon James Samuel | Director | $92.2K | $0 | 2026-03-26 |
| Russo Rene | CEO | $24.7K | $0 | 2025-06-16 |
| Frankenfield Christopher James | CFO | $0 | $11.3K | 2026-01-02 |
| Atlas Venture Fund XI, L.P. | 10% owner | $0 | $4.2K | 2024-02-08 |
| Brennan Kevin M. | EVP / SVP | $0 | $2.9K | 2026-01-02 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2021-10-26 | 6 | $36.2M | 50 | +21.0% (+21.6% raw) | -7.4% (-12.6% raw) | -71.0% (-76.6% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.